U.S. Markets open in 50 mins


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
56.67+1.35 (+2.45%)
At close: 3:46PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close55.31
Bid0.00 x 0
Ask0.00 x 0
Day's Range56.13 - 56.93
52 Week Range44.41 - 59.73
Avg. Volume21,751
Market Cap20.644B
Beta (5Y Monthly)0.39
PE Ratio (TTM)24.94
EPS (TTM)2.27
Earnings DateN/A
Forward Dividend & Yield0.76 (1.41%)
Ex-Dividend DateMay 07, 2021
1y Target EstN/A
  • PR Newswire

    UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

    UCB announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BRIVIACT (brivaracetam) CV tablets, oral solution, and injection to treat partial-onset seizures in patients as young as one month of age.2 This is the first time that the IV formulation of BRIVIACT will be available for pediatric patients when oral administration is temporarily not feasible and is the only IV formulation FDA-approved to treat partial-onset seizures in children one month

  • Benzinga

    UCB Gets EU Approval For Bimekizumab In Psoriasis

    The European Commission has cleared UCB's (OTC: UCBJF) Bimzelx (bimekizumab) for moderate to severe plaque psoriasis in adults. UCB's confidence lies in head-to-head studies that pitted Bimzelx against Novartis AG's (NYSE: NVS) Cosentyx (secukinumab) and found that it was better at achieving complete clearance of skin lesions at both 16 and 48 weeks. Bimekizumab is approved at a recommended dose of 320 mg, administered by two subcutaneous injections every four weeks to week 16 and every eight we

  • PR Newswire

    "The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

    UCB, a global biopharmaceutical company, announced today that The New England Journal of Medicine has published two manuscripts with results from BE RADIANT and BE SURE, two Phase 3 studies evaluating the efficacy and safety profile of bimekizumab, its investigational IL-17A and IL-17F inhibitor, in the treatment of adults with moderate to severe plaque psoriasis.1,2 Results from the Phase 3b BE RADIANT study were also shared today as a late-breaking oral presentation at the American Academy of Dermatology Virtual Meeting Experience 2021.3 BE RADIANT is the first Phase 3 study to compare the efficacy and safety of dual IL-17A and IL-17F inhibition versus IL-17A inhibition alone.1